Analyst Believes Biopharma's Alzheimer's Treatment Could Be Superior to Biogen's
Source: Streetwise Reports  (12/10/19)
How this company's Alzheimer's therapeutic compares to an advanced-stage competitor is outlined in a Dawson James Securities note. More >

ArQule Shares Double on Proposed $2.7 Billion Tender Offer from Merck
Source: Streetwise Reports  (12/9/19)
ArQule Inc. shares traded more than 100% higher today after the company entered into definitive agreement to be acquired by a Merck subsidiary company for $20 per share. The deal is valued at $2.7 billion and is expected to close in the early part of Q1/20. More >

Antibiotic Alternative for Livestock Feed Approved for Malaysia
Source: Streetwise Reports  (12/7/19)
Now, the company has the green light to sell this product in eight countries. More >

Imagin Medical Poised for Breakout with Bladder Cancer Detection Device
Source: Knox Henderson for Streetwise Reports  (12/6/19)
A new advancement in bladder-related endoscopic surgery is endorsed and de-risked. More >

Cassava Sciences' Shares Trade Up 20% on Updated Phase 2a Alzheimer's Data
Source: Streetwise Reports  (12/6/19)
Shares of Cassava Sciences traded 20% higher after the firm presented additional data from the Phase 2a study of its investigational drug candidate PTI-125 for Alzheimer's disease to the Clinical Trials on Alzheimer's Disease conference in San Diego, Calif. More >

Aurinia Pharma Shares Open 100% Higher on Phase 3 Lupus Data
Source: Streetwise Reports  (12/5/19)
Shares of Aurinia Pharmaceuticals traded much higher today after it reported positive results from its Phase 3 AURORA trial of Voclosporin for treatment of lupus nephritis. The company plans to submit a New Drug Application to the FDA in H1/20. More >

Immuno-Oncology Firm Expands Agreement with AbbVie
Source: Streetwise Reports  (12/4/19)
The revisions to the existing arrangement between the two U.S. firms are discussed in a ROTH Capital Partners report. More >

Company Vies for New Brunswick Cannabis Contract
Source: Streetwise Reports  (12/4/19)
The opportunity is one of the largest in retail cannabis in Canada. More >

Cannabis Producer Signs Supply Contract with Province of Alberta
Source: Streetwise Reports  (12/4/19)
To start, the company will introduce its premium brand of dried flower there. More >

INmune Bio Targeting Cancer, Alzheimer's and NASH Simultaneously
Source: Daniel Carlson for Streetwise Reports  (12/4/19)
Daniel Carlson of Tailwinds Research initiates coverage on this clinical-stage biotech whose drug candidate works to strengthen the innate immune system. More >

Protagonist Therapeutics Shares Trade Up 70% on Phase 2 Transfusion Trial Results
Source: Streetwise Reports  (12/4/19)
Newark, Calif.-based Protagonist Therapeutics' shares traded 70% higher today after the firm reported preliminary Phase 2 results for Hepcidin Mimetic PTG-300 in the treatment of transfusion dependent beta-thalassemia. More >

Axsome Therapeutics Investors Awaken to Positive Outcome in Phase 2 Narcolepsy Trial
Source: Streetwise Reports  (12/3/19)
Axsome Therapeutics shares traded 14% higher today after the company reported that its narcolepsy drug candidate AXS-12 achieved its primary endpoint in the Phase 2 CONCERT Study. More >

Kodiak Shares Soar on $225 Million Royalty Deal for Retinal Drug
Source: Streetwise Reports  (12/2/19)
Shares of Kodiak Sciences traded more than 100% higher at times after the company reported that it entered into a $225 million royalty agreement for the firm's KSI-301 used in the treatment of retinal vascular diseases including age-related macular degeneration and diabetic eye diseases. More >

Healthcare Tech Firm Expands Client Base in Texas
Source: Streetwise Reports  (11/26/19)
The company signs six new contracts for its telemedicine-based platform. More >

Coverage Initiated on Maker of Antibiotic-Free Supplement for Livestock Feed
Source: Streetwise Reports  (11/26/19)
The highlights of this investment story are outlined in a Zacks Small-Cap Research report. More >

ChemoCentryx Shares Spike 300% on Phase 3 ANCA Vasculitis Trial Results
Source: Streetwise Reports  (11/26/19)
Shares of ChemoCentryx Inc. opened greater than 330% higher today after the firm reported positive topline data from its pivotal Phase 3 ADVOCATE trial of Avacopan in treatment of ANCA-associated vasculitis. More >

Regenerative Medicine Firm Advances Multifaceted Pipeline
Source: Streetwise Reports  (11/26/19)
The company continues advancing its cell therapies and medical device. More >

Intercept Pharma Shares Rise on FDA Acceptance of NDA for Liver Fibrosis Treatment
Source: Streetwise Reports  (11/25/19)
Shares of Intercept Pharmaceuticals rose today after the company reported that the U.S. Food and Drug Administration accepted its NDA for obeticholic acid (OCA) for the treatment of liver fibrosis due to NASH and granted priority review status. More >

EyeGate Pharma Shares Looking Up on Pivotal PRK Ocular Bandage Gel Study Data
Source: Streetwise Reports  (11/22/19)
EyeGate Pharmaceuticals shares opened nearly 85% higher today after the company reported select topline data demonstrating that it met its primary endpoint in its cornea wound repairs pivotal photorefractive keratectomy study using the firm's Ocular Bandage Gel eye drop. More >

Cannabis Firm's Stock Poised for 'Substantial Gains'
Source: Clive Maund for Streetwise Reports  (11/21/19)
Technical analyst Clive Maund charts how news from this company affects its investment thesis. More >

Hepion Pharma Shares Climb 50% Higher on NASH Liver Disease Treatment Results
Source: Streetwise Reports  (11/21/19)
Shares of Hepion Pharmaceuticals opened higher today after the company reported that its anti-fibrotic agent CRV431 prevented the development of liver cirrhosis in a highly aggressive, preclinical liver disease model. More >

ICAN Leverages Leading California Brand with Expansion into Nevada, Introduces State-of-the-Art Pre-Roll Machine, for Aggressive Near-Term Growth
Source: Knox Henderson for Streetwise Reports  (11/20/19)
A recent acquisition is helping this company to expand its brand. More >

Kiniksa Pharma Awarded FDA Breakthrough Therapy Status for Pericarditis Treatment Drug
Source: Streetwise Reports  (11/20/19)
Shares of Kiniksa Pharmaceuticals opened nearly 30% higher today after the firm reported that the FDA granted Breakthrough Therapy designation for Rilonacept for the treatment of recurrent pericarditis. More >

Myovant Sciences Shares Up 110% on Phase 3 Advanced Prostate Cancer Data
Source: Streetwise Reports  (11/19/19)
Shares of Myovant Sciences opened 120% higher today after the firm reported a 97% response rate in its Phase 3 HERO Study of oral Relugolix in men with advanced prostate cancer. In the study, Relugolix achieved all six key secondary endpoints and the firm expects to submit a New Drug Application in Q2/20. More >

Medical Small Cap Moving Forward with Cutting-Edge Technological Innovations
Source: Streetwise Reports  (11/18/19)
Premier Health is methodically building an innovative telemedicine platform in Canada, is purchasing a venerable telemedicine firm, and sees 2020 as the year of execution. More >